Information Provided By:
Fly News Breaks for August 7, 2019
GWPH
Aug 7, 2019 | 05:10 EDT
GW Pharmaceuticals reported Q2 Epidiolex revenue of $68.4M, which "crushed "the consensus estimate of $45.5M, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst continues to be impressed by the Epidiolex launch trajectory and believes "any concerns of a plateau should now be diminished." She expects volume growth to continue over the second half of 2019 and reiterates an Overweight rating on shares of GW Pharmaceuticals with a $210 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH